On May 19, 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) reported that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences (Press release, BioLineRx, MAY 19, 2016, View Source;p=RssLanding&cat=news&id=2169697 [SID:1234512569]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An abstract titled "Clinical response in relapsed/refractory AML patients correlates with leukemic blast mobilization and differentiation induced by BL-8040, a potent CXCR4 antagonist; results of a Phase 2a study" was accepted for a poster presentation at the European Hematology Association (EHA) (Free EHA Whitepaper) 21st Congress, to be held June 9-12, 2016 in Copenhagen, Denmark. Full detailed results from this Phase 2a study will be presented at an upcoming US-based scientific conference.

An abstract titled "CXCR4 Controls BCL-2 Expression and Function by Regulating miR-15a/16-1 Expression in Tumor Cells," illustrating BL-8040’s mechanism of action, was accepted for an oral presentation at Chemotactic Cytokines Gordon Research Conference, to be held between May 29 – June 3, 2016, in Girona, Spain.